Non-small cell lung cancer: C-erbB-2 Overexpression correlates with low angiogenesis and poor prognosis

Anticancer Research

Volumn 16, Issue 6 B, 1996, Pages 3819-3826

  Giatromanolaki, Alexandra ^a,c   Koukourakis, Michael I ^b,c   O'Byrne, Ken ^b   Kaklamanis, Loukas ^a   Dicoglou, Christina ^c   Trichia, Eleni ^a   Whitehouse, Ruth ^b   Harris, Adrian L ^b   Gatter, Kevin C ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b CHURCHILL HOSPITAL   (United Kingdom)

^c UNIVERSITY HOSPITAL OF IRAKLION   (Greece)

Author keywords

Angiogenesis; C erbB 2; EGFR; Non small cell lung cancer

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

ADENOCARCINOMA; ADULT; AGED; ANGIOGENESIS; ARTICLE; CANCER GRADING; CANCER SURVIVAL; CELL MIGRATION; CONTROLLED STUDY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; METASTASIS; ONCOGENE C ERB; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; SURVIVAL TIME; TUMOR VASCULARIZATION;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; SURVIVAL ANALYSIS;

EID: 0030508511     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Schechter AL, Stern DF, Vaidyanathan L et al: The neu oncogene: an erb-B-related gene encoding a 185.000-Mr tumor antigen. Nature 316:513-516, 1984.
2. Akiyarna T, Sudo C, Ogawara H, Toyoshima K, Yamamoto T: The product of c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science 232: 1644-1646, 1986.
3. Kraus MH, Issing W, Miki T, Popescu NC, Aaronson SA: Isolation and characterisation of c-erbB-3, a third member ofthe erbB epidermal growth factor receptor family: evidence of overexpression in a subset of human mammary tumors. Proc Natl Acad Sci USA 86: 9193-9197, 1989.
4. Horak E, Smith K, Bromley L, LeJeune S, Greenall M, Lane D, Harris AL: Mutant p53, EGF receptor and c-erbB-2 expression in human breast cancer. Oncogene 6: 2277-2284, 1991.
5. Wright C, Mellon K, Johnston P, Lane DP, Harris AL, Horne CHW, Neal DE: Expression of mutant p53, c-erbB-2 and epidermal growth factor receptor in transitional cell carcinoma of the human urinary bladder, Br J Cancer 63:967-970, 1991.
6. Tateishi M, Ishida T, Mitsudomi T, Kaneko S, Sugimachi K: Prognostic value of c-erbB-2 protein expression in human lung adnocarcinoma and squamous cell carcinoma. Eur J Cancer 27: 1372-1375, 1991.
7. Tateishi M, Ishida T, Kohdono S, Hamatake M, Fukuyama Y, Sugimachi K: Prognostic influence of the co-expression of epidermal growth factor receptor and c-erbR-2 protein in human lung adenocarcinoma. Surg Oncol. 3:109-113, 1994.
8. Kern JA, Slebos RJC, Top B, Rodenhuis S, Lager D, Robinson RA, Weiner D: C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas. J Clin Invest 93:516-520, 1994.
9. Jou YS, Layhe B, Matesic DF, Chang CC, delFeijter AW, Lockwood L, Welsch CW, Klaunig JE, Trosko JE: Inhibition of gap junctional intercellular communication and malignant transformation of rat liver epithelial cells by neu oncogene. Carcinogenesis 16:311-317, 1995.
10. Ochiai A, Akimoto S, Kanai Y, Shibata T, Oyama T, Hirohashi S: C-erbB-2 gene product associates with catenins in human cancer cells. Biochem Biophys Res Commun 205:73-78, 1944.
11. Bernstein JJ, Goldberg WJ, Laws ER Jr: Migration of fresh human malignant astrocytoma cells into hydrated gel wafers in vitro. J Neurooncol 18:151-161, 1993.
12. de-Porter CR, Ecckhout I, Schelfhout AM, Geerts ML, Roels HJ: Keratinocyte induced chemotaxis in the pathogenesis of Paget's disease of the breast. Histopathology 24:349-356, 1994.
13. De-Porter CR. The neu oncogene: more than a prognostic indicator ? Hum Pathol 25: 1264-1268, 1994.
14. Horak E, Leek R, Klenk N, LeJeune S, Smith K, Stuart N, Greenal M, Stepniewska K, Harris AL: Angiogenesis, assessed by platelet, endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breastcancer. Lancet 340: 1120-1124, 1992.
15. Machiarini P, Fontanini G, Hardin MT, Squartini F, Angeleti CA: Relation to metastasis of non-small cell lung cancer. Lancet 340:145-146, 1992.
16. Giatromanolaki A, Koukourakis M, O'Byrne K, Fox S, Whitehouse R, Talbot D, Harris AL, Gatter KC: Prognostic value of angiogenesis in operable non-small cell lung cancer. J Pathol 179:80-88, 1996.
17. Veale D, Aschroft T, Gibson GJ, Harris AL: Epidermal growth factor receptors in non-small cell lung cancer. Br J Cancer 55:513-516, 1987.
18. Giatromanolaki A, Gorgoulis V, Ranjan C, Koukourakis M, Whitehouse R, Gatter KC, Iordanoglou: c-erbB-2 expression in non-small cell lung cancer. Anticancer Res. 16:987-994, 1986.
19. Mountain CF: A new international staging system for lung cancer. Chest 89(Suppl):225-233, 1986.
20. Waterfield MD, Mayers ELV, Stroobant P, Bennet PL, Young S, Goodfellow PN, Banting G, Ozanne B: A monoclonal antibody to the human epidermal growth factor receptor. Cell Biochem 20:149-161, 1982.
21. Corbett IP, Henry JA, Angus B et al: NCL-CB11, a new monoclonal antibody recognising the internal domain of the c-erbB-2 oncogene protein effective for use on formalin fixed, paraffin embedded tissue. J Pathol 161:15-25, 1990.
22. Kay EW, Barry Walsh CJ, Curran B, Leader M: C-erbB-2 immunostaining: problems with interpretation J Clin Pathol 47:816-822, 1994.
23. Parums DV, Cordell JL, Micklem K, Heryet AR, Gatter KC, Mason DY: JC70: a new monoclonal antibody that detects vascular endothelium associated antigen on routinely processed tissue sections. J Clin Pathol 43:752-757. 1990. in operable non small cell lung cancer. J Pathol. 1995 (in press)
24. Parums DV, Cordell JL, Micklem K, Heryet AR, Gatter KC, Mason DY: JC70: a new monoclonal antibody that detects vascular endothelium associated antigen on routinely processed tissue sections. J Clin Pathol 43:752-757. 1990. in operable non small cell lung cancer. J Pathol. 1995 (in press)
25. Challcley H: Method for the quantative morphological analysis of tissues. J Natl Cancer Inst 4:47-53, 1943.
26. Folkman J: Vascularisation of tumors. Sci Am 234:58-73, 1976.
27. Craft PS, Harris AL. Clinical prognostic significance of tumour angiogenesis. AnnOncol 5:305-311, 1944.
28. D'Amore PA: Antiangiogenesis as a strategy for antimetastasis. Sem Thromb Hemostas 14:73-78, 1988.
29. Yamazaki K, Abe S, Takekawa H, Sukoh N, Watanabe N, Ogura S, Nakajima I, Isobe H, Inoue K, Kawakami Y: Tumor angiogenesis in human lung adenocarcinoma. Cancer 74: 2245-2250, 1994.
30. Fidler IJ, Hart IR: Biologic diversity in human neoplasmes: origins and implications. Science 217:998, 1982.
31. Shimoyama Y, Hirohashi S: Expression of E- and P-cadherin in gastric carcinomas. Cancer Res 51: 2185-2142, 1991.
32. Takeishi M: The cadherins: cell-cell adhesion molecules controlling animal morphogenesis. Development 102:634-655, 1988.
33. Effect of epidermal growth factor on cadherin-mediated adhesion in a human oesophageal cancer cell line. Br J Cancer 71:250-258, 1995.
34. Kanai Y, Ochiai A, Shibata T, Oyama T, Ushijima S, Akimoto S, Hirohashi S: C-erbB-2 gene product directly associates with betacatenin and plakoglobin. Biochem Biophys Res Commun 208: 1067-1072, 1995.
35. Veal D, Kerr N, Gibson GJ, Harris AL: The relationship of quantitative epidermal growth factor receptor expression in non-small cell lung cancer to long term survival. Br J Cancer 68:162-165, 1993.
36. Costello P, McCann A, Carney DN, Dervan PA: Prognostic significance of microvessel density in lymph node negative breast carcinoma. Human Pathol 26: 1181-1184, 1995.
37. Umbas R, Isaacs WB, Bringuier PP, Schaafsma E, Karthaus HFM, Oosterhof GON, Debruyne MJ, Schalken JA: DecreasedE-Cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res 54: 3929-3933, 1994.
38. Basolo F, Fiore L, Calvo S, Conadi PG, Toniolo A: Effect of cytokines on normal and oncogene transfected human epithelial cells. EACR-12:12th Biennial Meeting of the European Association for Cancer Research, April 4-7, 1993. Brussels, Belgium, 1993.
39. Smith DR, Polverini PJ, Kunkel SL, Orringer MB, Whyte RI, Burdick MD, Wilke CA, Stricter RM: Inhibition of Interleukin 8 attenuates angiogenesis in bronchogenic carcinoma. J Exp Med 179: 1409-1415, 1994.
40. Yoshino I, Goedegebure PS, Peoples GE, Parikh AS, DiMaio J, Lyerly K, Gazdar AF, Eberlein TJ: HER2/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer. Cancer Res 54: 3387-3390, 1994.